Divi's Labs - Building ‘Growth Engines’ For Sustainable Earnings Momentum: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Divi's Laboratories Ltd. has had a successful track record, with a leading market share in the supply of large volume active pharma ingredients, on the back of proactive capacity addition, technology upgrades driving cost-efficiency, consistent compliance, and robust supply chain management.
It is still supplying these legacy products, showing both its strength and continuing demand in these products.
Divi's Labs' next leg of growth is expected to come from 16 new molecules it is currently working on.
Particularly Iohexol (under validation), is an interesting product, which finds application in the contrast media space and has only three drug master filers to date, thus offering a reasonable business opportunity.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.